Sagimet Biosciences Inc - Series A — Cash Flow (NASDAQ:SGMT) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Cash from operating activities -23.77 M-42.44 M -44.84 M Cash from investing activities 12.58 M-61.68 M 48 K Cash from financing activities 86.17 M104.82 M — Free cash flow -23.77 M-42.44 M -44.84 M

Notizie

Azioni Sagimet in rialzo dopo dati positivi sulla sicurezza del farmaco per l’acne

Sagimet stock rises after positive Phase 3 safety data for acne drug

Ascletis reports positive long-term safety data for acne drug denifanstat

Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT)

Sagimet riporta risultati positivi di Fase 1 per terapia combinata contro MASH

Sagimet reports positive Phase 1 results for MASH combination therapy

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)

Sagimet Biosciences executive chairman sells $290k in shares

Obiettivo di prezzo di Sagimet Biosciences alzato a $35 da Citizens

Sagimet Biosciences stock price target raised to $35 by Citizens

Denifanstat raggiunge tutti gli endpoint nello studio di fase 3 sull’acne in Cina

Denifanstat meets all endpoints in phase 3 acne trial in China